anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The impact of antidepressants on Inflammatory bowel diseases (IBD) has been extensively studied. However, the biological effects and molecular mechanisms of antidepressants in alleviating colitis remain unclear.
METHODS: We systematically assessed how antidepressants (fluoxetine, fluvoxamine and venlafaxine) affected IBD and chose fluoxetine, the most effective one, for mechanism studies. We treated the C56BL/6 mice of the IBD model with fluoxetine and their controls. We initially assessed the severity of intestinal inflammation in mice by body weight loss, disease Activity Index scores and the length of the colon. The H&E staining and immunohistochemical staining of MUC2 of colon sections were performed to observe the pathological changes. RT-qPCR and western blot were conducted to assess the expression level of the barrier and inflammation-associated genes. Then, single-cell RNA sequencing was performed on mouse intestinal mucosa. Seurat was used to visualize the data. Uniform Manifold Approximation and Projection (UMAP) was used to perform the dimensionality reduction. Cell Chat package was used to perform cell-cell communication analysis. Monocle was used to conduct developmental pseudotime analysis. Last, RT-qPCR, western blot and immunofluorescence staining were conducted to test the phenomenon discovered by single-cell RNA sequencing in vitro.
RESULTS: We found that fluoxetine treatment significantly alleviated colon inflammation. Notably, single-cell RNA sequencing analysis revealed that fluoxetine affected the distribution of different cell clusters, cell-cell communication and KEGG pathway enrichment. Under the treatment of fluoxetine, enterocytes, Goblet cells and stem cells became the dominating cells. The pseudotime analysis showed that there was a trend for M1 macrophages to differentiate into M2 macrophages. Lastly, we tested this phenomenon in vitro, which exhibited anti-inflammatory effects on enterocytes.
CONCLUSIONS: Fluoxetine exhibited anti-inflammatory effects on intestinal mucosa via remodeling of the intestinal cells and macrophages, which reveals that fluoxetine is a promising therapeutic drug for the treatment of IBD and psychiatric comorbidities.
Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial. Patients' rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.
NEW MATERIAL:A protein having a sequence of 20 amino acid residues at the N-terminal expressed by the formula, about 49,000mol.wt. measured by an electrophoresis (SDS-PAGE), about 63,000mol.wt. measured by a gel filtration method (TSK Gel G 3000SWXL(R)) and cell growth inhibitory activity. USE:An immunosuppressive agent and anticancer agent. PREPARATION:For example, TTK-1 cell strain which is a human placental decidual cell is cultivated using a 10% bovine fetal serum-containing culture medium and centrifuged to collect a cultivation supernatant, which is then ultrafiltered and concentrated. The resultant concentrate is subsequently salted out with ammonium sulfate to provide a deposited fraction, which is then dissolved in a 0.01M phosphoric acid buffer solution and purified by gel filtration, ion exchange chromatography, high-speed liquid chromatography and hydrophobic chromatography, etc., to afford the aimed human placental decidual cell- derived protein.
Herein is described a specific amino acid sequence which exhibits specific Ion (bridge) pair arrays enclosed on at least one side by non polar hydrophobic transmembrane segments, as a mechanism used by many infectious agents and a number of cytokine inhibitory factors, such as Interleukin 10 and Prolactin Inhibitory factor and alfa-fetoprotein, to not only undermine the hosts immune defences but to also allow for the infection of target lymphoid tissue. It has been demonstrated that certain vaccines, when inoculated into a host, produced a range of neutralising antibodies but failed to prevent infection when that host is later challenged with live infectious organism. This present patent illustrates that when such vaccine inoculation is coupled with passive immunisation with mono or polyclonal antibodies to these specific amino acid sequences as specified herein that the host is then capable of overcoming the infectious challenge. Herein is described the therapeutic use of mono or polyclonal antibodies to these said specific sequences as a treatment for Acquired Immune Deficiency Syndrome (AIDS) and other disease states that persist due to the presence of a cytokine inhibitory factor of viral, fungal, bacterial or host origin such as Chronic Fatique Syndrome where Interleukin 10 mimic molecules are responsible for a multitude of disease symptoms identified as indicative of Myalgic Encephalitis. Herein is described the therapeutic use of mono or polyclonal antibodies to these specific amino acid sequences as a combination therapy with vaccines and anti-viral agents to prevent side effects from certain immune modulation and anti-viral agents (e.g. DHEA and IL-12) which cause enhanced production of Interleukin 10 or AFP mimic molecules during therapy. Also herein is described the therapeutic use of these specific sequences either isolated from the organism source or produced by direct synthesis or recombinant protein synthesis. These peptides when administered to a patient suffering from an auto-immune disease, such as Multiple Sclerosis (MS), Lupus (systemic Lupus erythematoses) or diabetes or rheumatoid arthritis as limited examples or to transplant organ recipients, will allow the patient's immune state to be shifted to a Th2 antibody dependent immune response and curtail the Th1 (T cell dependent) immune attack which is evident in such immune malfunctions as MS and graft versus host disease. Certain dermatological conditions which are today treated by the use of corticosteroid creams and ointment may also be successfully treated by replacing the corticosteroid with these mimic immunosuppressive AFP/Interleukin 10 sequences outlined in this patent.
PURPOSE:To obtain a food additive, composed of an extract solution extracted from powdery beans or herbs with water and capable of stably inhibiting an angiotensin converting enzyme converting angiotensin I in bodies into angiotensin II having pressor action. CONSTITUTION:A food additive is composed of an extract solution prepared by extracting powdery beans or herbs with water. Seeds of Phaseolus coccineus L, leaves of apple geranium and flowers of Tropaeolum majus L. are preferred as the beans or herbs. The ratio of the beans or herbs to water is preferably 30-50 pts.wt. water to 1 pt.wt. (dry weight) beans or herbs. Thereby, the objective extract solution capable of exhibiting a high level of enzymic activity inhibitory function is preferably obtained.
Although less frequent than esophageal varices, gastric varices constitute a severe and potentially life threatening complication of portal hypertension. Various methods have been described to treat gastric varices, including endoscopic and interventional radiology techniques. Endoscopic variceal obliteration (EVO) is currently considered as standard of care for the treatment of gastric varices in most centers. However, this technique is associated with significant rebleeding rates and incomplete obliteration is observed in about 50% of patients. Alternatively, few centers also use an interventional radiology technique, called balloon-occluded retrograde transvenous obliteration (B-RTO) to treat gastric varices, which has been shown to be associated with less recurrence of gastric varices and high rates of eradication of about 90%. Both techniques have their inherent weaknesses, such as frequent incomplete eradication of varices and thromboembolic events for EVO, while data suggest that B-RTO may aggravate esophageal varices.

The aim of this pilot study is to evaluate the efficacy and safety of combined and simultaneous endoscopic variceal obliteration together with (modified) B-RTO. Stopping the outflow of gastric varices by endovascular balloon occlusion may allow better endoscopic visualization, blood stagnation and thus eradication of varices, while preventing thromboembolic events. Furthermore, during study follow-up, the eradication rates and recurrence of varices, short-term and long term complications, effects of the procedure on portal pressures/hemodynamics and liver function will be evaluated.
In this study, using a large database, we examined the association between atrial fibrillation (AF) in hospitalized patients with pulmonary hypertension (PH) and in-hospital mortality and other adverse hospital outcomes. This study was a retrospective analysis of the United States National (Nationwide) Inpatient Sample from 2005 to 2014. All hospitalizations for patients diagnosed with primary PH and over the age of 65 years were included and then grouped based on the presence AF. The outcomes were in-hospital mortality rate, hospital length of stay, and hospitalization costs. Weighted regression analyses were performed to find the association between AF and outcomes. Of the 5,428,332 hospitalizations with PH, 2,531,075 (46.6%) had concomitant AF. The Cox proportional regression analysis showed that in patients with PE, all-cause mortality (hazard ratio 1.35, confidence interval [CI] 1.15 to 1.55) was significantly higher in patients with AF than those without AF. In addition, PH hospitalizations with AF had a longer hospital length of stay (β coefficient 1.74, 95% CI 1.58 to 1.83) and higher hospitalization cost (β coefficient 1.33, 95% CI 1.12 to 1.42). In patients aged over 65 years admitted for PH, the presence of AF was very frequent and worsened the prognosis. In conclusion, to improve patient outcomes and decrease hospital burden, it is important to consider AF during risk stratification for patients with PH to provide timely and prompt interventions. An interdisciplinary approach to treatment should be used to account for the burden of co-morbidities in this population.
Despite advances in secondary prevention, a wide variety of vascular grafts available, and evolving surgical techniques, long-term efficacy of CABG is hampered by bypass graft failure and native CAD progression. Therefore, patients with prior CABG often present with recurrent ischemic symptoms. Indeed, many prior CABG patients undergo repeat cardiac catheterization and require subsequent revascularization therapy. The clinical evaluation and diagnostic work-up of patients with recurrent angina after CABG is challenging. Patients with previous CABG are generally older, have a higher prevalence of cardiac risk factors and comorbidities, more extensive CAD, and complex atherosclerotic lesion morphology. Furthermore, current guideline recommendations on patient management are limited since post-CABG patients have often been underrepresented or excluded in large diagnostic and revascularization trials. This registry will include patients presenting with recurrent ischemic symptoms with a history of CABG and ≥1 SVGs that are referred to the Amsterdam University Medical Centers. Patients will be eligible for inclusion in the VIADUCT registry after consideration of in- and exclusion criteria. Subsequently, patients will be approached for study participation. Patients are free to refuse or to withdraw from participation in the registry at any moment. The primary objective is to investigate clinical outcomes in patients with recurrent symptoms who are evaluated for bypass graft failure and native CAD progression. In addition, results from non-invasive and invasive diagnostic tools that are used during clinical work-up to assess graft patency, the hemodynamic significance of native CAD progression, left ventricular function, and myocardial viability will be collected. We aim to evaluate the value of such tools to guide optimal repeat revascularization strategy.
This study investigates the role of autophagy-related genes (ARGs) in bladder cancer (BLCA), focusing on the regulator of G protein signaling 19 (RGS19). Using data from The Cancer Genome Atlas (TCGA) and the Human Autophagy Database (HADb), we identified RGS19 as significantly upregulated and linked to poor prognosis in BLCA. Kaplan-Meier survival analysis confirmed its association with increased mortality and. In vitro, RGS19 knockdown in BLCA cell lines inhibited proliferation, migration, and invasion, while inducing apoptosis and autophagy. Transmission electron microscopy showed autophagic structures in RGS19-silenced cells. In vivo, a xenograft mouse model demonstrated reduced tumor growth with RGS19 knockdown. Immunohistochemical (IHC) analysis revealed decreased Ki67 and increased autophagy markers in tumors with reduced RGS19. Pathway analysis suggested RGS19 acts through the cGMP-PKG signaling pathway, validated by altered expression of soluble guanylate cyclase (sGC), protein kinase G (PKG1), phosphodiesterase 5 A (PDE5A), vasodilator-stimulated phosphoprotein (VASP), and phosphorylated VASP (p-VASP) upon RGS19 knockdown. These results highlight RGS19 as a potential biomarker and therapeutic target in BLCA.
The invention relates to the field of traditional Chinese medicines, in particular to a kidney recovering capsule and a preparation method thereof. The method comprises the following steps: (1) raw materials: glabrous greenbrier rhizome, pagodatree flower, lalang grass rhizome, motherwort herb and cablin potchouli herb. (2) Pulverizing rhizoma Smilacis Glabrae and herba Agastaches into fine powder. (3) Taking the rest three materials of the sophora flower, the cogongrass rhizome and the motherwort with a specified amount, adding 6 times of water, carrying out hot reflux extraction for 3-5 hours, filtering, and carrying out vacuum concentration at 60 ℃ to obtain clear paste with the relative density of 1.25. (4) Mixing the fine powder and fluid extract, vacuum drying at 55 deg.C, pulverizing, adding adjuvants, mixing, and making into capsule. Each granule of the product contains flos Sophorae Immaturus and rutin (C) 27 H 30 O 16 ) Calculated as more than 1.50 mg. The obtained medicine has higher content of effective components than conventional method, and can reduce product dosage and extractThe product has high curative effect and high economic benefit.
PROBLEM TO BE SOLVED: To obtain a proteolytic enzyme-containing hydrous cosmetic excellent in usability without imparting a dry and rough feeling or a tight feeling by using a proteolytic enzyme having high stability in an aqueous solution. SOLUTION: This proteolytic enzyme-containing hydrous cosmetic is characterized as comprising the proteolytic enzyme chemically modified with a water-soluble high polymer and a surfactant. Any proteolytic enzyme derived from a microorganism, a plant or an animal can be used and, e.g. a protease derived from a mold, a papain or a pepsin is cited. The enzyme preferably has the optimal pH value especially in a neutral or an alkaline region. Furthermore, boric acid or borax may be contained.
There is a potential for immunogenicity with ADZYNMA. Patients may develop neutralizing antibodies to ADAMTS13, which could potentially result in a decreased or lack of response to ADAMTS13. Neutralizing antibodies were not reported in the cTTP clinical trials. All subjects had been previously exposed to ADAMTS13 through plasma-based products. There are no data on immunogenicity with ADZYNMA in previously untreated patients (subjects naïve to plasma-based products) [see Clinical Pharmacology (12.6)].

Patients may develop antibodies to host cell proteins which could potentially result in adverse reactions. There are no data on immunogenicity to host cell proteins in previously untreated patients (subjects naïve to plasma-based products).
The present invention relates to the field of blood products, in particular fibrinogen and fibrinogen pharmaceutical products. The present invention provides a dry, e.g. lyophilized, fibrinogen drug product having a residual moisture content of 2-5% (w/w). The inventors have found that the moisture content facilitates virus inactivation by dry heat, which results in a particularly virus safe and stable product. The invention also provides a dry, e.g., lyophilized, fibrinogen drug product having an extremely low number of sub-visible particles (SVP), as well as batches of such drug product. Which is suitable for reconstitution of 1g fibrinogen in water for injection to obtain a fibrinogen solution comprising 6000 or less SVPs having a size of 10-100 μm and 600 or less SVPs having a size of 25-100 μm. Also disclosed are methods of preparing the pharmaceutical products of the invention, and the use of these pharmaceutical products for the treatment of fibrinogen deficiency.
Chest physiotherapy and mobilisation were applied on the patients for 4 days. The treatment of the patients was started on the first postoperative day and continued until the postoperative 4th day.
The first 10-minute of Slow Art Plus involves a brief psychoeducation on slow looking, mindfulness, and self-compassion practices. This is followed by a 10-minute participants self-introduction and sharing of one act of self-kindness; a 10-minute facilitator led mindfulness meditation on affectionate breathing to foster greater somatic and emotional clarity for slow-looking. This is followed by a set of 30-minute slow looking activity with 1 selected art-piece, including: (a) creating an Artwork Title with one sentence description, (b) imaging music that resonates with the viewers' emotional response to artwork, and (c) sketching a Response Art that facilitates a dialogue between the viewer and the art piece for perspective widening. A 10-minute dyadic sharing follows with a 5-minute large group sharing of joint collective experience. Artwork reveal and sharing of its self-care implications is offered. Finally, a closure self-compassion activity of Supportive Healing Touch.
Participants will receive sham tACS twice daily for one week. Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
Forty subjects will be enrolled at Senegal site.In Senegal site, 20 males and 20 females will be recruited respectively. The samples will comprise individuals aged 18-50. Half will be male and half female. Half of the samples will be collected in 'summer' (June, July and August) and half in 'winter' (October, November and December). The same individuals will not be measured in both seasons.
Systems and methods for assessing patient-specific evolution of resistance to therapy and progression of disease in recurrent high-grade glioma patients are described herein. An example method includes receiving a plurality of patient-specific parameters for a patient having recurrent high-grade glioma. The patient-specific parameters include an evolution of resistance rate to a In combination therapy, a pre-treatment tumor volume, and a radiation surviving fraction. The method also includes simulating, for each of a plurality of radiation therapy protocols, a respective volumetric tumor growth trajectory for the patient. The simulation is performed using a tumor growth model based on the patient-specific parameters. The method further includes determining an optimal radiation therapy protocol based on the simulation, wherein the optimal radiation therapy prolongs progression of the recurrent high-grade glioma.
This study investigated the therapeutic benefits of para-hydroxycinnamic acid in mice with bleomycin-induced lung fibrosis. Forty male BALB/c mice were randomly assigned to four groups: normal, which received 0.9% normal saline; induced, which received a single dose of bleomycin (5 mg/kg) by oropharyngeal challenge; pirfenidone-treated; and para-hydroxycinnamic acid-treated, which challenged with bleomycin and received a daily oral dose of 300 and 50 mg/kg, respectively, from day 7 to day 21. Tissue pro-fibrotic and inflammatory cytokines, oxidative indicators, pulmonary histopathology, immunohistochemistry of fibrotic proteins and the assessment of gene expression by RT-qPCR were evaluated on day 22 after euthanizing animals. Pirfenidone and para-hydroxycinnamic acid managed to alleviate the fibrotic endpoints by statistically improving the weight index, histopathological score and reduced expression of fibrotic-related proteins in immune-stained lung sections, as well as fibrotic markers measured in serum samples. They also managed to alleviate tissue levels of oxidative stress and inflammatory and pro-fibrotic mediators. para-Hydroxycinnamic acid enhanced the expression of crucial genes associated with oxidative stress, inflammation and fibrosis in vivo. para-Hydroxycinnamic acid has demonstrated similar effectiveness to pirfenidone, suggesting it could be a promising treatment for fibrotic lung conditions by inhibiting the TGF-β1/Smad3 pathway or through its anti-inflammatory and antioxidant properties.
Within the scope of this technique, first of all, the participants were asked to focus on a word that relieves them such as love, health or well-being. And so, the participants were asked to be in comfortable position in a silent and breathable room with the closed eyes, relax their muscles from the sole of their feet and progressing up to their face gradually, keep them relaxed, accompanied with deep breathing, be aware of their breathing, exhale gently. They continue these practices for 20 minutes and try to relax their muscles. After finishing the duration, they sit quietly for several minutes with eyes closed and later with eye opened.
To successfully develop disease-modifying therapies (DMT) against Alzheimer's disease (AD), it is important to target the mild stage of the disease, before the pathological changes progress and dementia symptoms are fully manifested. To this end, the AD Neuroimaging Initiative (ADNI), a large-scale observational study, was initiated in the U.S. with the goal of development of DMT that are effective in the early stages of mild cognitive impairment (MCI) by utilizing imaging and biomarkers. In Japan, J-ADNI enrolled and followed up 537 patients, mainly with MCI, and established a platform for evaluation including amyloid PET, and demonstrated a high similarity in the clinical course of amyloid-positive MCI (prodromal AD) in Japan and the U.S. In 2023, the anti-Aβ antibody lecanemab successfully completed a Phase III clinical trial for early AD (prodromal AD + mild AD dementia) and was granted regulatory approval and made available both in the US and Japan. Also, phase III trial of donanemab was completed successful. The J-TRC study was initiated in Japan as a "trial ready cohort (TRC)" consisting of participants who met the eligibility criteria for participation in preclinical and prodromal AD trials. Based on such a platform, the development of DMT for AD will progress more rapidly in the future.